<SEC-DOCUMENT>0001104659-24-079691.txt : 20240715
<SEC-HEADER>0001104659-24-079691.hdr.sgml : 20240715
<ACCEPTANCE-DATETIME>20240715074514
ACCESSION NUMBER:		0001104659-24-079691
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240715
FILED AS OF DATE:		20240715
DATE AS OF CHANGE:		20240715

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			I-Mab
		CENTRAL INDEX KEY:			0001778016
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39173
		FILM NUMBER:		241115870

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 400, 2440 RESEARCH BLVD
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(301) 670 2800

	MAIL ADDRESS:	
		STREET 1:		SUITE 400, 2440 RESEARCH BLVD
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2419452d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16 OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Month of July, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: 001-39173</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>I-MAB</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2440 Research Blvd, Suite 400</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Rockville,
MD 20850</B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F </FONT><FONT STYLE="font-family: Wingdings">&#120;</FONT> &nbsp;&nbsp; Form 40-F <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 9%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 90%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt"><A HREF="tm2419452d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><A HREF="tm2419452d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release of I-Mab, dated July 15, 2024</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: July 15, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I-MAB</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 45%">&nbsp;</TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Joseph Skelton</FONT></TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph Skelton</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2419452d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt"><IMG SRC="tm2419452d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>I-Mab Announces Leadership Transitions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ROCKVILLE, MD, July 15, 2024</B> &ndash; I-Mab
(NASDAQ: IMAB) (the &ldquo;Company&rdquo; or &ldquo;I-Mab&rdquo;), a U.S.-based, global biotech company, announced today that the Board
of Directors of the Company has appointed Mr. Wei Fu as the Chairman of the Board of Directors. He succeeds Dr. Pamela M. Klein, who steps
down from I-Mab&rsquo;s Board of Directors and the Interim Chairperson position. Mr. Wei Fu has served as a member of the I-Mab Board
of Directors since June 2018 and is the Chief Executive Officer of CBC Group, a healthcare asset management firm and the founding and
largest shareholder of I-Mab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, Mr. Raj Kannan intends to leave his
role as Chief Executive Officer and as a member of the Company&rsquo;s Board of Directors, effective July 15, 2024. Mr. Kannan will stay
as an advisor of the Company until July 31, 2024 to assist with the transition. This decision follows a mutual agreement with the Board
of Directors. Dr. Sean Xi-Yong Fu has assumed the role of Interim Chief Executive Officer and a member of the Board of Directors, effective
July 15, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to being Interim CEO and Director
of I-Mab, Dr. Sean Fu is also an Operating Partner of ABio-X, an incubation platform for life sciences companies. Before joining ABio-X,
Dr. Fu was co-founder and CEO of RVAC Medicines, an mRNA platform company. Prior to founding RVAC, Dr. Fu was Group VP and head of International
R&amp;D for Luye Pharma, overseeing organizations in Boston, Princeton, Germany, Switzerland and Japan. He was also the CEO of GeneLeap,
a Luye subsidiary company focused on DNA and RNA therapeutics. Previously, Dr. Fu worked at Merck &amp; Co. for 15 years with responsibilities
covering R&amp;D, business development, finance and operational management. His work at Merck included management of the finances for
the late-stage clinical portfolio and leading the integration of global R&amp;D network following the landmark $42 billion merger between
Merck and Schering-Plough. Dr. Fu earned a Master&rsquo;s and PhD degrees in materials science and engineering from Ohio State University,
and an MBA from the Wharton School of University of Pennsylvania.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Our dedication to scientific innovation
and to our strategic objectives for bringing life-changing drugs to market is unwavering,&rdquo; said Mr. Wei Fu, I-Mab&rsquo;s new Chairman.
&ldquo;I am confident Dr. Fu will provide invaluable leadership for our talented team in advancing our innovative R&amp;D pipeline and
our business in his role as Interim CEO. He brings a wealth of biotech industry experience and relationships to support the Board as we
secure the best permanent leader to take I-Mab forward and drive our growth opportunities and value for shareholders. Meanwhile, we&rsquo;d
like to extend our gratitude to Ms. Klein and Mr. Kannan for their support and contributions to I-Mab.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;I&rsquo;m grateful for this opportunity
and excited to lead I-Mab. During this pivotal time, I am dedicated to leading I-Mab through the completion of its transformation to becoming
a U.S.-based biotech company, to build the Company&rsquo;s highly differentiated pipeline, and work with our Board of Directors, leadership
team and talented employees and partners to create new treatment options for patients around the world,&rdquo; said Dr. Sean Fu, Interim
CEO of I-Mab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to these leadership transitions, the
Company also announced certain changes to the composition of the Board of Directors and its committees:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the resignations of Dr. Ruyi He and Professor Rong Shao as Directors, and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the appointments of Mr. Wei Fu and Mr. Conor Chia-hung Yang as new members of the compensation committee
with Mr. Wei Fu being the Chairman thereof, and Mr. Sean Xi-Yong Fu as a new member of the ESG committee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After the transitions, the Company&rsquo;s Board
of Directors will consist of Mr. Wei Fu (Chairman), Dr. Sean Xi-Yong Fu, Mr. Chun Kwok Alan Au, Mr. Conor Chia-hung Yang, and Mr. Shuai
Chen. The Company&rsquo;s audit committee will consist of Mr. Yang (Chairman), Mr. Au, and Mr. Chen. The Company&rsquo;s nominating and
corporate governance committee consists of Mr. Wei Fu (Chairman), Mr. Au, and Mr. Yang. The compensation committee will consist of Mr.
Wei Fu (Chairman), Mr. Au, and Mr. Yang, and the ESG committee will consist of Mr. Au (Chairman) and Mr. Sean Xi-Yong Fu.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About I-MAB</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech
company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment
of cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I-Mab has established operations in the U.S.
in Rockville, Maryland, and in San Diego, California. For more information, please visit <U>https://www.i-mabbiopharma.com</U> and follow
us on LinkedIn and X.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains forward-looking statements.
These statements are made under the &ldquo;safe harbor&rdquo; provisions of the U.S. Private Securities Litigation Reform Act of 1995.
These forward-looking statements can be identified by terminology such as &ldquo;will&rdquo;, &ldquo;believes&rdquo;, &ldquo;dedication&rdquo;,
&ldquo;objectives&rdquo;, &ldquo;intends&rdquo;, &ldquo;potential&rdquo;, &ldquo;determined to&rdquo;, and similar terms or the negative
thereof. Forward-looking statements are based on I-Mab&rsquo;s current expectations and assumptions. Because forward-looking statements
relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from
those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of
future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements
are set forth in filings with the U.S. Securities and Exchange Commission. I-Mab undertakes no obligation to publicly update or revise
any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>I-Mab Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investors &amp; Media</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tyler Ehler</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Senior Director, Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IR@imabbio.com</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2419452d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2419452d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !+ +H# 2(  A$! Q$!_\0
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M)I'5!N44V<+\6YFB\!SHO26:-#],Y_I7AED"CJZG# @BO??B?9->^ [[:,M
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M1\W;GUI1%&K[U10V N0.<>E-U/(%3?<Q_#$^[3GLG$BR64A@*R##!>J9_P"
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%10!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
